Does tourism development contribute to the green water-use efficiency of the Yellow River Basin in China?

The coordination between economic development as well as water resources conservation in ecologically fragile areas is the basis for achieving sustainable development in developing countries. Nonetheless, the existing literature pays little attention to such an issue. The purpose of this quantitative study is to explore the causal relationship between tourism development and green water-use efficiency in the Yellow River Basin (YRB) of China. The findings are as follows: (1) Tourism development can significantly enhance the green water-use efficiency in the YRB; For every 1% increase in tourism revenue, the green water-use efficiency will increase by 4.38%. (2) Tourism affects the green water-use efficiency by increasing the intensity of water pollution and decreasing the intensity of water use; For every 1% increase in tourism revenue, the green water-use efficiency will decrease by 0.2% and increase by 0.9% respectively by increasing the intensity of water pollution and decreasing the intensity of water use. (3) Strengthening environmental regulation and improving service facilities will further enhance the positive impact of tourism development; An increase of one standard deviation in the intensity of environmental regulation or one standard deviation in the level of service facilities will increase the impact of tourism on green water-use efficiency by 1.1% or 1.7%, respectively. The aforementioned findings provide enlightenment for effectively promoting the coordination between economic development and water resources protection in ecologically fragile areas of developing countries.

A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma.

Hepatocellular carcinoma (HCC), a highly malignant digestive system tumor, poses substantial challenges due to its intricate underlying causes and pronounced post-surgery recurrence. Consequently, the prognosis for HCC remains notably unfavorable. The endorsement of sorafenib and PD-L1 inhibitors for HCC signifies the onset of a new era embracing immunotherapy and targeted treatment approaches for this condition. Hence, comprehending the mechanisms underpinning targeted immune combination therapy has become exceedingly vital for the prospective management of HCC patients. This article initially presents a triumphant instance of curative treatment involving the combination of TKI and PD-1 inhibitor subsequent to liver resection, targeting an advanced stage HCC as classified by the BCLC staging system. The case patient carries a decade-long history of hepatitis B, having undergone a regimen of 20 courses of treatments involving apatinib and camrelizumab. Throughout the treatment period, no occurrences of grade 3 or 4 adverse events (AE) were noted. Subsequently, the patient underwent a left hepatectomy. Following the hepatectomy, their serum AFP levels have consistently remained within normal limits, and CT imaging has indicated the absence of tumor recurrence over a span of 36 months. The patient had been reviewed on time for two years after the operation. The last time a CT was performed for this patient in our hospital was 7 May 2021, and no new tumors were found. Follow-up is still ongoing. When applying combined targeted immune transformation therapy using TKI and ICI for a patient with BCLC advanced stage HCC, apatinib treatment serves a dual purpose. It inhibits the survival and angiogenesis of tumor cells, while also enhancing the efficacy of camrelizumab in obstructing the interaction between PD-1 and PD-L1. This restoration of T cell cytotoxicity subsequently facilitates the elimination of tumor cells, leading to an enhanced anticancer effect.

Recent advances in the intracellular delivery of macromolecule therapeutics.

Intracellular delivery of macromolecules is a critical procedure for biological research and drug discovery, including proteins, peptides, vaccines, antibodies and genes. The penetration of macromolecule therapeutics through the cell membrane to intracellular targets is a prerequisite for their biological activity, but most delivery systems rely on the endocytic pathway to enter the cell and confront an inability to escape from the lysosome. A profound understanding of the cellular internalization of transporting carriers can (i) optimize the design of drug delivery systems, (ii) maintain the biological activity of biomolecular drugs, (iii) improve the efficiency of intracellular macromolecule transport and release, (iv) bring new opportunities for the discovery of macromolecule therapeutics and treatment of refractory disease. This article summarizes the uptake pathway of intracellular delivery vehicles for macromolecule drugs, hoping to provide ideas and references for macromolecule therapeutics delivery systems.